The continuous acceleration of domestic pharmaceutical equipment going overseas will drive the continued high growth of the company’s performance

In recent years, China's pharmaceutical equipment industry has developed rapidly, from the extensive production model in the past to the current high-precision, high-quality and stable development.
With the continuous transformation and upgrading of the industry, China's pharmaceutical equipment industry has ushered in a period of accelerated development.

.
At the same time, the performance of related pharmaceutical machinery companies has also shown a trend of continuous growth
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) According to statistics, in the first three quarters, Chutian Technology's revenue was 3.
68 billion yuan, a year-on-year increase of 67.
24%, and its net profit reached 400 million yuan, a year-on-year increase of 723.
53%; Tofflon's revenue was 2.
882 billion A year-on-year increase of 54.
61%, net profit of 558 million yuan, a year-on-year increase of 93.
69%; Canaan Technology’s revenue of 752 million yuan, a year-on-year increase of 24.
50%, and a net profit of 57.
68 million yuan, a year-on-year increase of 10.
63%
.
On the whole, China's pharmaceutical equipment industry is continuing to develop well, but at the same time, some people in the industry have pointed out that the industry is facing many challenges such as serious product homogeneity and increasingly fierce market competition
.
It is worth noting that, in this context, related companies have invested in overseas markets in order to seek new growth points and enhance and expand market development space
.
For example, Chutian Technology has already started an international strategic layout through the acquisition of Romaco of Germany
.
During the epidemic, downstream customers Zhifei Longkoma, Zhongsheng Group and other new factories overseas also brought Chutian Technology the opportunity to accelerate its overseas market layout
.
According to statistics, in the first half of 2021, Chutian Technology's revenue in the Americas has increased by more than 70% year-on-year
.
It is worth mentioning that on July 21st, Chutian Technology also stated in an institutional survey that in the next 3-5 years, the company plans to maintain an annual increase of 10%-20% in its export business.
It is planned to be around 2025.
The export business income of this department accounts for 40%-50% of the total income
.
The company will achieve this plan by improving product technology, quality and international services
.
Combining the 2021 semi-annual report of Tofflon, it is also obvious that its performance in overseas markets is getting more and more outstanding. .
Specifically, in the first half of 2021, Tofflon's overseas revenue reached 448 million yuan, accounting for 24.
75% of the company's operating revenue, and the revenue growth rate in Europe increased by more than 3.
1 times year-on-year
.
The analysis shows that the company's product gross profit margins in Europe, Africa, and North America have all exceeded 50%.
The gross profit margin of the South American market, which ranks at the bottom, has reached 30%.
The average gross profit rate of products sold to four overseas continents has increased year-on-year.
More than 20%
.
In the context of achieving outstanding results, Tofflon staff also publicly stated that the focus of biopharmaceuticals in China and even the world in the future will still be in the field of innovative drugs.
Among them, the preparation of biomedical solutions and the output of engineering capabilities are the track for rapid market demand growth.
Therefore, the company will set up a team to continue to meet the needs of the domestic and foreign markets
.
At present, the rapid development of Tofflon, Tofflon and other companies in overseas markets is allowing more and more companies to see new opportunities
.
It is reported that many companies have also made it clear that they will accelerate the internationalization of domestic pharmaceutical equipment
.
From the perspective of the industry, in the future, more and more domestic pharmaceutical equipment companies will actively deepen their international layout and accelerate the expansion of the export scale of domestic pharmaceutical equipment
.
However, technological level is the key to internationalization.
Therefore, a large number of pharmaceutical machinery companies are currently working on the high-end market with the intention of enhancing their competitiveness
.
After all, standing in the forefront of technology updates can better grasp the market
.
In fact, the domestic pharmaceutical equipment industry in the past has always presented a "small", "scattered" and "chaotic" market pattern, which has also led to the market being mostly small and medium-sized enterprises, with large enterprises accounting for a relatively small proportion and uneven product quality.
And so on
.
At present, accelerating the expansion of overseas markets and guiding the development of pharmaceutical equipment to the high-end market has become the consensus of all parties.
The industry expects that relevant companies will increase R&D investment one after another, and will continue to accelerate while continuing to advance into the high-end field.
Domestic substitution and export, realizing further growth of overseas business
.